COPENHAGEN, Denmark; June 9, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab – Form 6-K & More News Here

COPENHAGEN, Denmark; June 9, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab.

This new arbitration follows from the award within the prior arbitration, the place the tribunal dominated in favor of Janssen on the query as as to if Genmab is required to share in Janssen’s royalty funds to Halozyme Therapeutics, Inc. for its expertise used within the subcutaneous formulation of daratumumab (marketed as DARZALEX FASPRO^® within the United States), cf. Company Announcement No 14. The tribunal primarily based its ruling on the discovering that DARZALEX FASPRO constitutes a new licensed product under the license agreement.

In this new arbitration, Genmab is consequently searching for an award of $405 million plus curiosity in accrued milestone funds for DARZALEX FASPRO and a declaration that it is entitled to a new 13-12 months royalty time period from the date of DARZALEX FASPRO‘s first industrial sale.

Under the agreement, the arbitration shall be performed in New York pursuant to the foundations of the CPR Institute for Dispute Resolution for Non-Administered Arbitration earlier than a panel of three arbitrators. While Genmab intends to vigorously implement its rights, the result of any arbitration continuing, in addition to its period, is inherently unsure. The arbitration shall be confidential, topic to the events’ disclosure obligations under relevant legislation. Other than pursuant to those obligations, Genmab doesn’t intend to remark or present further data concerning the arbitration till an award on the deserves or different materials order is issued within the arbitration or the arbitration is in any other case concluded. While the arbitration is pending, Genmab’s numerous collaborations with Janssen will proceed.

About Genmab

Genmab is a global biotechnology firm with a core objective to enhance the lives of individuals with most cancers. For greater than 20 years, Genmab’s imaginative and prescient to rework most cancers remedy has pushed its passionate, modern and collaborative groups to invent subsequent-era antibody expertise platforms and leverage translational analysis and knowledge sciences, fueling a number of differentiated most cancers remedies that make an impression on folks’s lives. To develop and ship novel therapies to sufferers, Genmab has fashioned 20+ strategic partnerships with biotechnology and pharmaceutical firms. Genmab’s proprietary pipeline consists of bispecific T-cell engagers, subsequent-era immune checkpoint modulators, effector perform enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with areas in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For extra data, please go to Genmab.com and comply with us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs

T: +1 609 524 0065; E: [email protected]

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: [email protected]

Genmab Commences New Arbitration Under License Agreement With Janssen

This Company Announcement accommodates ahead trying statements. The phrases “believe”, “expect”, “anticipate”, “intend” and “plan” and related expressions determine ahead trying statements. Actual outcomes or efficiency might differ materially from any future outcomes or efficiency expressed or implied by such statements. The essential elements that may trigger our precise outcomes or efficiency to vary materially embrace, amongst others, dangers related with pre-scientific and scientific improvement of merchandise, uncertainties associated to the result and conduct of scientific trials together with unexpected questions of safety, uncertainties associated to product manufacturing, the dearth of market acceptance of our merchandise, our lack of ability to handle progress, the aggressive setting in relation to our enterprise space and markets, our lack of ability to draw and retain suitably certified personnel, the unenforceability or lack of safety of our patents and proprietary rights, {our relationships} with affiliated entities, adjustments and developments in expertise which can render our merchandise or applied sciences out of date, and different elements. For a additional dialogue of those dangers, please seek advice from the chance administration sections in Genmab’s most up-to-date monetary reviews, which can be found on www.genmab.com and the chance elements included in Genmab’s most up-to-date Annual Report on Form 20-F and different filings with the U.S. Securities and Exchange Commission (SEC), which can be found at www.sec.gov. Genmab doesn’t undertake any obligation to replace or revise ahead trying statements on this Company Announcement nor to verify such statements to mirror subsequent occasions or circumstances after the date made or in relation to precise outcomes, except required by legislation.

​
Genmab A/S and/or its subsidiaries personal the next emblems: Genmab^®; the Y-formed Genmab brand^®; Genmab together with the Y-formed Genmab brand^®; HuMax^®; DuoBody^®; DuoBody together with the DuoBody brand^®; HexaBody^®;HexaBody together withthe HexaBody brand^®; DuoHexaBody^®and HexElect^®; DARZALEX FASPRO^®is a trademark of Johnson & Johnson.